Non-Small Cell Lung Cancer

Featured

Conference Coverage
Treatment Patterns After EGFR-TKI and Platinum-Based Chemotherapy Discontinuation in Metastatic NSCLC
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Conference Coverage
Biomarker Testing-Guided Treatment Improves Outcomes in Advanced or Metastatic NSCLC
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or…
Conference Coverage
Real-World Use of Pembrolizumab Plus Chemotherapy for NSCLC
Patients with NSCLC who receive pembrolizumab with chemotherapy are more likely to remain on therapy past 90 days than…
Quiz
Quiz: High OOP Costs for Patients With NSCLC
True or False: Higher out-of-pocket costs for TKIs among patients with epidermal growth factor receptor- and anaplastic…
Guideline Updates
NCCN Updates Clinical Practice Guideline for Central Nervous System Cancers
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a…

News

Higher Out-of-Pocket Costs Associated With Decreased TKI Adherence in NSCLC
Anticancer Therapy Small Driver of Unplanned Hospital Care for Patients With NSCLC
Timely Specialty Palliative Care for NSCLC Associated With Cost-Savings
NGS Panel Using ctDNA Accurately Identifies Key Driver Alterations in Advanced NSCLC

Guideline Updates

NCCN Updates Clinical Practice Guideline for Central Nervous System Cancers

Interviews

Assessing a New Potential Standard of Care in First-Line Metastatic, Non-Squamous NSCLC

Videos

Exploring the New IVI NSCLC Value Modeling Platform

Podcast

Episode 28: Advances in NSCLC With Nathan Pennell

Conference Coverage

Nivolumab Plus Ipilimumab Associated With Lower Costs Than Other First-Line Regimens for NSCLC
Back to Top